Qilian International Holding Group Limited (QLI)

Market Cap	16.09M
Revenue (ttm)	61.93M
Net Income (ttm)	1.48M
Shares Out	35.75M
EPS (ttm)	0.04
PE Ratio	11.25
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,684
Open	0.465
Previous Close	0.490
Day's Range	0.430 - 0.500
52-Week Range	0.370 - 2.140
Beta	1.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2023

About QLI

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral soluti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 12, 2021
• Employees: 345
• Stock Exchange: NASDAQ
• Ticker Symbol: QLI

Financial Performance

In 2022, QLI's revenue was $64.86 million, an increase of 13.58% compared to the previous year's $57.10 million. Earnings were $1.08 million, a decrease of -65.85%.